However, PAH is associated with reduced NO availability and reduced sensitivity of the sGC as caused by oxidative stress that may restrict the effectiveness of PDE5 inhibitors (Hoeper, Simonneau, & Corris, 2017; Lang, Kojonazarov, & Tian, 2012). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.